Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1478-1489
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1478
Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
Aditya Borakati, Farid Froghi, Ricky H Bhogal, Vasileios K Mavroeidis
Aditya Borakati, Department of Surgery, The Royal London Hospital, Barts Health NHS Trust, London E1 1FR, United Kingdom
Farid Froghi, Department of HPB and Liver Transplantation Surgery, Royal Free Hospital NHS Foundation Trust, London NW3 2QG, United Kingdom
Ricky H Bhogal, Vasileios K Mavroeidis, Department of Academic Surgery, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, United Kingdom
Author contributions: Mavroeidis VK conceptualised and designed the study; Borakati A did the literature search; Borakati A and Froghi F did the analysis, interpretation of data and drafted the original manuscript; Bhogal RH and Mavroeidis VK supervised and made critical revisions; all authors prepared the final draft and approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vasileios K Mavroeidis, MD, MSc, FRCS, FICS, MFSTEd, Surgeon, Department of Academic Surgery, The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, United Kingdom. vasileios.mavroeidis@nhs.net
Received: March 21, 2022
Peer-review started: March 21, 2022
First decision: April 25, 2022
Revised: May 7, 2022
Accepted: July 6, 2022
Article in press: July 6, 2022
Published online: August 15, 2022
Processing time: 142 Days and 11.9 Hours
Core Tip

Core Tip: Intrahepatic cholangiocarcinoma (iCCA) maintains a dismal prognosis despite best available therapy. Complete surgical resection offers a potentially curative option but is feasible in a limited number of cases. This review explores the evolving role of stereotactic ablative radiotherapy (SABR) in the management of iCCA either as an adjuvant to surgical resection, or in cases or recurrent or unresectable disease. Data on the use of SABR as a neoadjuvant/downstaging modality are scarce. Notably, published studies are limited to predominantly retrospective case series. High quality prospective trials evaluating SABR are urgently needed.